AIM
PRTK

Aigen Investment Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Aigen Investment Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,582
Closed -$79K – 949
2020
Q4 		$79K Buy
+12,582
New +$74K 0.01% 737

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aigen Investment Management's PRTK Position: Q1 2021 in Review

Aigen Investment Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2021, closing a stake of 12,582 shares — an estimated $79K sold.

Aigen Investment Management first reported a position in PRTK in Q4 2020 and held it in 1 quarter. The position peaked at $79K in Q4 2020. 107 funds tracked by Wall St. Rank hold PRTK as of Q1 2021.

  • Aigen Investment Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Aigen Investment Management sold 12,582 Paratek Pharmaceuticals, Inc. shares in Q1 2021, an estimated $79K.
  • Aigen Investment Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
  • Aigen Investment Management's Paratek Pharmaceuticals, Inc. position peaked at $79K in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2021.

Based on Aigen Investment Management's 13F filing for Q1 2021, filed 11 May 2021.